We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Potential Vaccine for Pollen-Related Allergies

By Biotechdaily staff writers
Posted on 21 May 2002
A potential vaccine for hay fever and other pollen-related allergies is being developed by researchers at the University of Melbourne (Australia). More...
The vaccine significantly reduces the allergenic response although it remains capable of boosting an immune response in the patient.

The research team initially isolated the gene responsible for the production of rye grass, one of the most potent environmental allergens known. By making small modifications to the gene, nine different mutant forms of the original wild-type protein were produced. The protein of one of these mutations (mut 9) produced an allergic response reduced at least tenfold in all patients, compared to the wild type. The mutated gene was placed in a bacterium, which could then produce the modified protein in large quantities. In its purified form the protein becomes a potential vaccine.

Skin prick tests suggest that the new vaccine is safer and more effective than current immunotherapy. The latter carries a risk of lethal side effects that include anaphylactic shock. Analysis showed that the body's immune system retained its ability to respond to and build immunity against the potent group 5 allergens to which rye grass belongs.
The research team discovered that some of the modified proteins can have even better results with some patients, which suggests that patients could be matched with a vaccine tailored to their immune system or individual sensitivity.

"Our results contribute to the concept of using major pollen allergens for allergen-specific immunotherapy and to the safe and effective forms of allergy treatment,” said
Professor Mohan Singh, co-group leader.



Related Links:
Univ. of Melbourne

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Hematology Consumables
Bioblood Devices
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.